5.1 Pharmacokinetics & Pharmacodynamics

[!NOTE] Curriculum Focus: The MRCP(UK) Part 1 examination consistently tests quantitative clinical pharmacology. Candidates must be proficient in calculating loading and maintenance doses, manipulating clearance and half-life formulas, identifying the physiological implications of volume of distribution and protein binding, recognizing capacity-limited zero-order elimination, and interpreting log concentration-response curves for various receptor ligands.

Pharmacology is traditionally divided into two reciprocal disciplines: pharmacokinetics (what the body does to the drug: absorption, distribution, metabolism, and excretion) and pharmacodynamics (what the drug does to the body: receptor binding, signal transduction, and physiological response).

---

Bioavailability and Drug Absorption

Bioavailability (F) is defined as the fraction or percentage of an administered drug dose that gains access to the systemic circulation in an unchanged, chemically active form:

Bioavailability (F) = (AUC_oral / AUC_IV) x (Dose_IV / Dose_oral) x 100%

Where AUC represents the Area Under the Plasma Concentration-Time Curve. For intravenous administration, bioavailability is 100% (F = 1.0) by definition. For oral administration, F is typically < 1.0 due to two physiological barriers:

1. Incomplete Transmucosal Absorption: Caused by poor gastrointestinal membrane permeability, physicochemical degradation (e.g., gastric acid degradation of benzylpenicillin), chelation with divalent cations (e.g., ciprofloxacin or doxycycline binding oral calcium or iron), or active mucosal efflux by apical P-glycoprotein (ABCB1).
2. First-Pass Hepatic Metabolism (Pre-systemic Extraction): Venous drainage from the stomach, small intestine, and upper rectum traverses the hepatic portal vein directly through the liver prior to entering the systemic circulation. Drugs with high hepatic extraction ratios (EH > 0.7) undergo extensive phase I/II enzymatic clearance on their first pass, drastically lowering systemic bioavailability:
   • High First-Pass Clearance Drugs: Propranolol (F ≈ 25%), lidocaine (F < 10%, hence unusable orally), morphine (F ≈ 20–40%), glyceryl trinitrate (F < 1%, mandating sublingual or transdermal delivery), verapamil, and salbutamol.
   • Clinical Implication: In severe hepatic cirrhosis with portosystemic shunting, the first-pass effect is lost, leading to dramatic elevations in peak plasma concentrations (Cmax) and unexpected toxicity from routine oral doses of high-clearance drugs.

---

Apparent Volume of Distribution (Vd)

The apparent volume of distribution (Vd) represents the theoretical volume of fluid into which an administered dose would need to be uniformly distributed to produce the observed initial plasma concentration (C0):

Vd = Dose_IV / C0 = (F x Dose_oral) / C0

Vd does not correspond to an anatomical fluid compartment; rather, it reflects the degree to which a drug partitions into extravascular tissues versus remaining sequestered within plasma.

Plasma Protein Binding and the Free Drug Fraction

Only the unbound (free) fraction of a drug can cross vascular membranes to reach therapeutic target receptors, undergo glomerular filtration, or enter hepatocytes for enzymatic biotransformation.

• Acidic Drugs: Bind predominantly to albumin (e.g., warfarin, phenytoin, salicylates, ceftriaxone, sulfonylureas).
• Basic Drugs: Bind predominantly to α1-acid glycoprotein (e.g., lidocaine, propranolol, verapamil, tricyclic antidepressants).

[!IMPORTANT] Hypoalbuminaemia & Critical Care Alterations: In nephrotic syndrome, cirrhosis, systemic sepsis, or severe malnutrition, albumin concentrations fall. For drugs that are > 90% protein-bound (such as phenytoin), total measured serum levels decrease because unbound drug distributes into tissue or is cleared. However, the biologically active free drug concentration often remains completely therapeutic or even supratherapeutic. Measuring total phenytoin without correcting for albumin (or directly checking free phenytoin) risks erroneous dose escalation and severe toxicity.

Loading Dose Formulation

The loading dose is designed to rapidly achieve the target therapeutic steady-state plasma concentration (C_target), bypassing the delay required by elimination half-life accumulation:

Loading Dose = (Vd x C_target) / F

Notice that the loading dose depends only on Vd and target concentration; it is completely independent of systemic drug clearance (CL). Therefore, in acute renal failure, the loading dose of digoxin or vancomycin remains identical to that in healthy individuals, whereas the subsequent maintenance doses must be drastically reduced.

---

Clearance (CL) and Elimination Kinetics

Clearance (CL) is the volume of plasma completely cleared of drug per unit of time (expressed in mL/min or L/h). Total systemic clearance represents the sum of all individual organ elimination pathways:

CL_total = CL_renal + CL_hepatic + CL_biliary + CL_other

Clearance is mathematically defined by the relationship between the rate of drug elimination and plasma drug concentration (C):

CL = Rate of Elimination / C = (F x Dose) / AUC

Maintenance Dose Rate

To maintain a constant target steady-state concentration (Css), the rate of drug input must precisely equal the rate of drug loss:

Dosing Rate (Maintenance) = (CL x Css) / F

Maintenance Dose per Interval (tau) = (CL x Css x tau) / F

---

Elimination Half-Life (t1/2) and Steady-State Dynamics

The elimination half-life (t1/2) is the time required for the plasma drug concentration to decrease by 50% under first-order elimination conditions. It is governed by both clearance and volume of distribution:

t1/2 = (0.693 x Vd) / CL

From this relationship, two vital clinical axioms emerge for the MRCP examination:

1. t1/2 is directly proportional to Vd: A drug with a massive volume of distribution (e.g., amiodarone, Vd ≈ 5000 L) will have a prolonged half-life (several weeks) even if organ clearance mechanisms are functional.
2. t1/2 is inversely proportional to CL: Severe renal impairment decreases aminoglycoside clearance, directly prolonging t1/2 and necessitating extended dosing intervals.

+-----------------------------------------------------------------------------------------+
|                         Accumulation to Steady State (Css)                              |
+-----------------------------------------------------------------------------------------+
| Time Elapsed:         Fraction of Steady State Attained:                                |
|   1 x t1/2            50.0 %                                                            |
|   2 x t1/2            75.0 %                                                            |
|   3 x t1/2            87.5 %                                                            |
|   4 x t1/2            93.75 %                                                           |
|   5 x t1/2            96.875 %  (Clinically considered steady state: > 95%)            |
+-----------------------------------------------------------------------------------------+

[!NOTE] Rule of 5 Half-Lives: Steady-state plasma concentration (Css) is reached after 4 to 5 half-lives of continuous regular dosing or constant infusion. Crucially, increasing the dose or increasing the rate of infusion does not allow steady state to be reached any faster; it merely produces a proportionately higher steady-state concentration. The time required to reach steady state is determined solely by the elimination half-life of the drug.

---

First-Order vs Zero-Order (Saturable) Kinetics

Understanding the mathematical divergence between linear and capacity-limited elimination is essential for diagnosing drug toxicities:

   Plasma Concentration (C)
       ^
       |        Zero-Order Phase
       |        (Rate = Vmax = Constant)
       |       /       Saturation point
       |      /        |
       |     /         v
       |    /          --------------------
       |   /          / First-Order Phase
       |  /          /  (Rate = CL x C)
       | /          /
       +-------------------------------------> Dose / Administration Rate

Clinical Disaster with Zero-Order Kinetics: Phenytoin

Phenytoin follows Michaelis-Menten elimination kinetics:

Rate of Elimination = (Vmax x C) / (Km + C)

Where Vmax is the maximum rate of hepatic enzymatic biotransformation (CYP2C9/2C19) and Km is the plasma concentration at which elimination is half-maximal (~20–30 μmol/L, which sits right inside the therapeutic range of 40–80 μmol/L [10–20 mg/L]).

• At low concentrations (C << Km), elimination is first-order.
• As concentrations enter the therapeutic window (C ≈ Km), enzyme saturation commences.
• At high therapeutic concentrations (C >> Km), enzymes are fully saturated (zero-order). At this point, a minor, seemingly harmless dose increment (e.g., from 300 mg to 350 mg daily) overwhelms hepatic clearance capacity, causing a catastrophic, exponential surge in plasma concentration leading to nystagmus, severe cerebellar ataxia, and coma.

---

Pharmacodynamics: Receptor Interactions & Concentration-Response Curves

Pharmacodynamics evaluates the relationship between drug concentration and biological effect. When biological effect is plotted against the logarithm of drug concentration (log[D]), a characteristic symmetrical sigmoidal (S-shaped) curve is generated.

Key Quantitative Definitions

• Efficacy (Emax): The maximal biological response produced by an agonist at receptor saturation. Reflects intrinsic biological activity.
• Potency (EC50): The concentration of drug required to produce 50% of its maximal effect. A lower EC50 signifies higher potency (the curve lies further to the left). Potency is governed by receptor affinity and spare receptor capacity.

Classification of Ligands and Functional Shifts

1. Full Agonist: Binds to receptors, stabilizes the active conformational state, and possesses an intrinsic efficacy of 1.0, achieving maximal tissue response (Emax = 100%).
2. Partial Agonist: Stabilizes the active conformation with lower intrinsic efficacy (0 < efficacy < 1.0). Even when 100% of receptors are occupied, a partial agonist cannot produce maximal tissue response. Clinical Pitfall: In the presence of a full agonist, a partial agonist competes for binding sites and acts as a competitive antagonist, shifting the full agonist's curve rightward while reducing overall response (e.g., buprenorphine attenuating full mu-opioid agonists, pindolol blunting catecholamines, varenicline competing with nicotine).
3. Inverse Agonist: Preferentially binds to and stabilizes the inactive conformation of constitutively active receptors (receptors that signal even without ligand binding, such as GABAA, cannabinoid, or histamine H2 receptors), driving basal signaling below baseline.
4. Competitive (Reversible) Antagonist:
   • Binds reversibly to the same orthosteric agonist binding pocket.
   • Dose-Response Effect: Produces a parallel rightward shift in the log concentration-response curve.
   • Parameters: EC50 is increased (apparent potency reduced); Emax remains unchanged (unaffected).
   • Mechanism: Can be completely overcome ("surmounted") by adding higher concentrations of agonist (e.g., naloxone competing with morphine; atropine competing with acetylcholine).
5. Non-Competitive (Allosteric or Irreversible) Antagonist:
   • Binds either irreversibly (covalently) to the active site (e.g., phenoxybenzamine at alpha-adrenoceptors) or reversibly to a separate allosteric site (e.g., ketamine at NMDA receptors).
   • Dose-Response Effect: Causes a downward crushing / depression of the curve.
   • Parameters: Emax is reduced; EC50 remains unchanged (or minimally altered).
   • Mechanism: Cannot be surmounted by increasing agonist concentration because available functional receptors are permanently silenced.

   Biological Effect (% Emax)
   100 +                     /-- Full Agonist Alone
       |                    / 
       |                   /   /-- Full Agonist + Competitive Antagonist
       |                  /   /    (Parallel Right-Shift: EC50 increased, Emax intact)
    50 |                 /   / 
       |                /   / 
       |  /-- Non-Comp /   / 
       | /   Antagonist
       |/ (Emax depressed)
     0 +-------------------------------------------> log [Drug Concentration]

Therapeutic Index (TI)

The margin of safety of a pharmaceutical compound is quantified by the Therapeutic Index:

Therapeutic Index = TD50 / ED50  or  LD50 / ED50

Where TD50 is the toxic dose in 50% of subjects, and ED50 is the therapeutically effective dose in 50% of subjects. Drugs with a narrow therapeutic index (e.g., warfarin, digoxin, lithium, theophylline, gentamicin, phenytoin, carbamazepine) require meticulous therapeutic drug monitoring (TDM) and precise dosing adjustment.